Disease · EFO_0009760

non-proliferative diabetic retinopathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. non-proliferative diabetic retinopathy. Diseases, record EFO_0009760. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009760

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: non-proliferative diabetic retinopathy
Open Targets ID: EFO_0009760
Other names: NPDR, background retinopathy, nonproliferative diabetic retinopathy
Highest stage of its drugs: Phase 3, for 5 of its 23 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AFLIBERCEPT	CHEMBL1742982	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
OCTREOTIDE ACETATE	CHEMBL1200480	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TARCOCIMAB TEDROMER	CHEMBL5095154	Antibody drug conjugate	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FARICIMAB	CHEMBL4297750	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
HYALURONIDASE	CHEMBL1201636	Enzyme	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LAZUCIRNON	CHEMBL3670800	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets59

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VEGFA	Vascular endothelial growth factor A, long form	5	Vascular endothelial growth factor A inhibitor	Phase 3	https://conductscience.org/library/genes/7422	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
PGF	Placenta growth factor	2	Placenta growth factor inhibitor	Phase 3	https://conductscience.org/library/genes/5228	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Unknown	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor	Unknown	https://conductscience.org/library/genes/5743	Drugs and targets
ANGPT2	Angiopoietin-2	1	Angiopoietin-2 inhibitor	Phase 2	https://conductscience.org/library/genes/285	Drugs and targets
COL11A1	Collagen	1	Collagen hydrolytic enzyme	Phase 2	https://conductscience.org/library/genes/1301	Drugs and targets
COL11A2	Collagen	1	Collagen hydrolytic enzyme	Phase 2	https://conductscience.org/library/genes/1302	Drugs and targets
COL15A1	Collagen	1	Collagen hydrolytic enzyme	Phase 2	https://conductscience.org/library/genes/1306	Drugs and targets
COL18A1	Collagen	1	Collagen hydrolytic enzyme	Phase 2	https://conductscience.org/library/genes/80781	Drugs and targets

1 to 10 of 59

See all 59 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01331681	Intravitreal Aflibercept Injection in Vision Impairment Due to DME	Phase 3	406	2014-09-09	Diabetes Mellitus, Macular Edema	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT02718326	Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)	Phase 3	402	2019-11-21	Nonproliferative Diabetic Retinopathy	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT05066230	A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)	Phase 3	253	2024-09-05	Non-proliferative Diabetic Retinopathy	TARCOCIMAB TEDROMER	Its record names the disease	ClinicalTrials.gov
NCT03197870	The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)	Phase 2	167	2023-06-27	Nonproliferative Diabetic Retinopathy	RAZUPROTAFIB	Its record names the disease	ClinicalTrials.gov
NCT02681809	A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR	Phase 2	48	2020-12-16	Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression	OCRIPLASMIN	Its record names the disease	ClinicalTrials.gov
NCT00917553	Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy	Phase 2	33	2018-11-30	Diabetic Retinopathy	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT05038020	A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)	Phase 2	3	2023-11-01	Diabetic Retinopathy	LAZUCIRNON	Its record names the disease	ClinicalTrials.gov
NCT05222633	Anti-VEGF in Real-world		1,000		Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy, Retinal Vein Occlusion, Proliferative Diabetic Retinopathy	AFLIBERCEPT, CONBERCEPT, RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00248131	Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy	Phase 3	260		Diabetic Retinopathy	OCTREOTIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT05681884	Safety and Efficacy of Faricimab in Patients With NPDR	Phase 2	179		Non-Proliferative Diabetic Retinopathy	FARICIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
KSI-301 - Treatment Group A vs Treatment Group B: Percentage of Patients Developing PDR or ASNV	2 of 128	10 of 125	253	NCT05066230	Trial comparisons
KSI-301 - Treatment Group A vs Treatment Group B: Percentage of Patients Developing Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR	2 of 128	3 of 125	253	NCT05066230	Trial comparisons
KSI-301 - Treatment Group A vs Treatment Group B: Percentage of Patients Improving ≥2 Steps on DRSS	52 of 128	2 of 125	253	NCT05066230	Trial comparisons
KSI-301 - Treatment Group A vs Treatment Group B: Percentage of Patients Developing DME	1 of 128	17 of 125	253	NCT05066230	Trial comparisons
KSI-301 - Treatment Group A vs Treatment Group B: Percentage of Patients Improving ≥3 Steps on DRSS	7 of 128	0 of 125	253	NCT05066230	Trial comparisons
KSI-301 - Treatment Group A vs Treatment Group B: Percentage of Patients Developing Any Sight-Threatening Complication	3 of 128	26 of 125	253	NCT05066230	Trial comparisons
KSI-301 - Treatment Group A vs Treatment Group B: Percentage of Patients Developing PDR	2 of 128	10 of 125	253	NCT05066230	Trial comparisons
Doxycycline Monohydrate vs Placebo: deaths from any cause	0 of 16	0 of 17	33	NCT00917553	Trial comparisons
Doxycycline Monohydrate vs Placebo: serious adverse events	8 of 16	4 of 17	33	NCT00917553	Trial comparisons
Doxycycline Monohydrate vs Placebo: Number of Participants Who Developed Vitreous or Preretinal Hemorrhage	0 of 15	0 of 15	30	NCT00917553	Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37007930	RESULT	1	PubMed
26198808	RESULT	1	PubMed
26056030	RESULT	1	PubMed
25012934	RESULT	1	PubMed
22595020	RESULT	1	PubMed
41587134	DERIVED	1	PubMed
37260074	DERIVED	1	PubMed
36265076	DERIVED	1	PubMed
34351414	DERIVED	1	PubMed
29785301	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009760

GET https://conductscience.org/api/diseases/v1/EFO_0009760/drugs?page=2

API reference For AI assistants